Eli Lilly & Co. 

(Public, NYSE:LLY)   Watch this stock   
Find more results for LLY
Apr 18, 2010
Q1 2010 Earnings Conference Call Add to calendar
Apr 18, 2010
Annual Meeting of Shareholders Add to calendar
Apr 18, 2010
Q1 2010 Earnings Release Add to calendar
Jan 28, 2010
Q4 2009 Earnings Conference Call
Jan 28, 2010
Q4 2009 Earnings Release
Jan 12, 2010
JPMorgan Healthcare Conference
Dec 21, 2009
Incyte Conference Call to Discuss Its Collaboration with Lilly - Webcast
Dec 10, 2009
Investment Community Meeting
Nov 12, 2009
Credit Suisse Healthcare Conference
More events from AOL Finance »    

Key stats and ratios

Q4 (Dec '09) 2009
Net profit margin 15.43% 19.82%
Operating margin 20.31% 25.59%
EBITD margin - -
Return on average assets - -
Return on average equity - -
Employees 40,800 -

Address

Lilly Corporate Center
Indianapolis, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
About Company - Wikipedia

Eli Lilly & Co. discussed on blogs

Eli Lilly & Co. discussions

  View all discussions »

Description

Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through owned or leased facilities in the United States, Puerto Rico and 25 other countries. Eli Lilly and Company’s products are sold in approximately 135 countries. The Company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Its principal products include Neurosciences products, Endocrinology products, Oncology products, Cardiovascular products, Animal health products and Other pharmaceuticals. On August 20, 2008, the Company acquired SGX Pharmaceuticals, Inc. (SGX). On November 24, 2008, the Company acquired ImClone Systems Inc. (ImClone), a biopharmaceutical company focused on advancing oncology care.

Officers and directors

John C. Lechleiter Ph.D.
Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation - Reuters
Derica W. Rice
Chief Financial Officer, Executive Vice President - Global Services
Age: 44
Bio & Compensation - Reuters
Frank M. Deane Ph.D.
President - Manufacturing Operations
Age: 59
Bio & Compensation - Reuters
David Ricks
President, Lilly USA, LLC
Bio & Compensation - Reuters
Bryce D. Carmine
Executive Vice President and President - Established Markets Business Unit
Age: 57
Bio & Compensation - Reuters
Jan M. Lundberg Ph.D.
Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Bio & Compensation - Reuters
Michael C. Heim
Senior Vice President - Information Technology, Chief Information Officer
Bio & Compensation - Reuters
Robert A. Armitage
Senior Vice President, General Counsel
Portrait. Age: 60
Bio & Compensation - Reuters
Thomas W. Grein
Senior Vice President, Treasurer
Age: 56
Bio & Compensation - Reuters
Sue Mahony Ph.D.
Senior Vice President - Human Resources
Bio & Compensation - Reuters